EYPT - EyePoint Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.4000
+0.0800 (+3.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.3200
Open2.3200
Bid2.35 x 1000
Ask2.61 x 800
Day's Range2.3000 - 2.5000
52 Week Range0.9300 - 3.9400
Volume332,547
Avg. Volume456,254
Market Cap227.949M
Beta (3Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-1.46
Earnings DateFeb 5, 2019 - Feb 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.17
Trade prices are not sourced from all markets
  • ACCESSWIRE14 days ago

    4 Pharma Stocks Raising Eyebrows (1/3/19)

    CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / With the new year only a few days old, the pharmaceutical industry is already buzzing with the excitement surrounding companies who are taking innovative approaches to create a variety of effective treatment options for patients in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Eyepoint Pharmaceuticals, Inc (NASDAQ: EYPT), Cocrystal Pharma Inc (NASDAQ: COCP), and Fred's, Inc (NASDAQ: FRED) are 4 pharma stocks to keep tabs on as the industry moves toward the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), a company that you may not have heard of, but could potentially benefit from looking into, recognizes the importance of investing in the future of the pharmaceutical industry, and amid this understanding, has made several key announcements in the past few months to show investors, as well as members of its 100,000 patient ecosystem, that the Company is committed to the advancement of this goal.

  • GlobeNewswire15 days ago

    EyePoint Pharmaceuticals Provides 2019 Commercial Update

    WATERTOWN, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) --  EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today provided a 2019 commercial update. “EyePoint has made significant progress in building its commercial infrastructure in preparation for two ophthalmic product launches in the near-term,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “As a result of the diligence with which our team has worked to execute on commercial manufacturing scale-up, communicate with payors, build our distribution network and our hub for patient and physician support, I am pleased to be able to announce that along with the launch of YUTIQTM in the first quarter of calendar 2019, we also now anticipate launching DEXYCUTM in the first quarter of calendar 2019, earlier than initially expected.

  • GlobeNewswirelast month

    EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index

    WATERTOWN, Mass., Dec. 17, 2018 -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options

    Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)  

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for DEXYCU™ (dexamethasone intraocular suspension) 9%. “The issuance of a specific and permanent J-code for DEXYCU is another key milestone for the Company that allows for a convenient and simplified reimbursement process that is familiar to administering physicians and the greater insurance community,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. The code, J1095, will become effective on January 1, 2019, and will replace the previously issued C-code for DEXYCU (C9034) that became effective on October 1, 2018.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

    WATERTOWN, Mass., Nov. 06, 2018 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -46.15% and -30.57%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga2 months ago

    The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 5) Allakos Inc (NASDAQ: ALLK ) Allogene Therapeutics Inc ...

  • Associated Press2 months ago

    EyePoint Pharmaceuticals: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 44 cents. Losses, adjusted for non-recurring costs, were 19 cents per share. The drug delivery technology company ...

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments

    -YUTIQ™ approved by U.S. FDA; anticipated launch in calendar 1Q19- -Exclusive license granted to Ocumension Therapeutics to develop and commercialize EyePoint’s three-year.

  • GlobeNewswire2 months ago

    EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region

    EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics today announced an exclusive license agreement for the development and commercialization of EyePoint’s three-year micro insert using the Durasert™ technology for chronic, non-infectious posterior segment uveitis in the greater China territory, which is comprised of China, Hong Kong, Macau and Taiwan. EyePoint received approval for this product by the U. S. Food and Drug Administration (FDA) on October 12, 2018, and will be marketing it in the U.S. under the brand name YUTIQ™.

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., Oct. 30, 2018 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment of John Landis, Ph.D., M.S., to the Company’s Board of Directors. Dr. Landis, a veteran pharmaceutical sciences executive, has led development functions including pharmacy, analytical chemistry, process chemistry, biotechnology, devices, clinical supplies, and quality assurance.

  • GlobeNewswire3 months ago

    EyePoint Pharmaceuticals Presents Positive YUTIQ™ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting

    EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of 24-month efficacy and safety data supporting the Company's YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. “Decreasing or eliminating uveitis flares is a critical factor in managing non-infectious posterior-uveitis as recurrences of attacks can lead to blindness if not properly treated.

  • EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq
    Zacks3 months ago

    EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq

    EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.

  • EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%
    Zacks3 months ago

    EyePoint Pharmaceuticals (EYPT) Catches Eye: Stock Jumps 6.8%

    EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Market Exclusive3 months ago

    Stock Market News Daily Roundup October 15

    Netflix, PayPal, IBM, Others Reporting This Week Many key companies are set to report earnings this week. Bank of America has reported its quarterly results today while Morgan Stanley, Goldman Sachs, Netflix, United Airlines, Johnson & Johnson, BlackRock, and IBM will report earnings on Tuesday. On Wednesday, earnings will be released by United Rentals and […] The post Stock Market News Daily Roundup October 15 appeared first on Market Exclusive.

  • Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for EyePoint Pharmaceuticals (EYPT) Stock Options

    Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.

  • GuruFocus.com4 months ago

    US Stocks Lower on Wednesday

    EyePoint Pharmaceuticals down more than 3% after reporting results

  • EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
    Zacks4 months ago

    EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

    EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -111.11% and 6.72%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?